광동제약

009290KOSPI

56.5 / 100

Reference Date: 2026-10-23

Financial Score24.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly up 4.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Guangdong Pharmaceutical operates through three divisions—OTC, ETC, and F&B—selling products like Cheongshimwon, Jeju Samdaewon, and Gardasil, with 98.6% of sales coming from the domestic market. In 2025, the company achieved sales of 10.11 trillion KRW and aims to expand into natural product markets, digital innovation, and healthcare platforms to become a 'Human Healthcare Brand' enterprise.

Number of Employees

1,022people

Average Salary

78.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.65Industry Average 15.005.0Point

In line with industry avg

PBR

0.46Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

3.21Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

11.61Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲4.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼12.7% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 5.7% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 6,590Won52-week high 11,08052-week low 5,270

1-month return4.0Point

1m +4.11% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-12
Neutral주식등의대량보유상황보고서(일반)2026-10-02